{"denoms":[{"counts":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"5"},{"groupId":"BG006","value":"4"},{"groupId":"BG007","value":"8"},{"groupId":"BG008","value":"7"},{"groupId":"BG009","value":"4"},{"groupId":"BG010","value":"5"},{"groupId":"BG011","value":"14"},{"groupId":"BG012","value":"7"},{"groupId":"BG013","value":"14"},{"groupId":"BG014","value":"57"},{"groupId":"BG015","value":"34"},{"groupId":"BG016","value":"15"},{"groupId":"BG017","value":"13"},{"groupId":"BG018","value":"24"},{"groupId":"BG019","value":"27"},{"groupId":"BG020","value":"19"},{"groupId":"BG021","value":"8"},{"groupId":"BG022","value":"103"},{"groupId":"BG023","value":"386"}],"units":"Participants"}],"groups":[{"description":"Participants with or without FGF/FGFR gene abnormalities received orally TAS-120 8 mg orally QOD (Monday, Wednesday and Friday of each week) in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.","id":"BG000","title":"Phase 1: Dose Escalation: QOD Dosing: 8 mg"},{"description":"Participants with or without FGF/FGFR gene abnormalities received orally TAS-120 16 mg orally QOD (Monday, Wednesday and Friday of each week) in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.","id":"BG001","title":"Phase 1: Dose Escalation: QOD Dosing: 16 mg"},{"description":"Participants with or without FGF/FGFR gene abnormalities received orally TAS-120 24 mg orally QOD (Monday, Wednesday and Friday of each week) in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.","id":"BG002","title":"Phase 1: Dose Escalation: QOD Dosing: 24 mg"},{"description":"Participants with or without FGF/FGFR gene abnormalities received orally TAS-120 36 mg orally QOD (Monday, Wednesday and Friday of each week) in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.","id":"BG003","title":"Phase 1: Dose Escalation: QOD Dosing: 36 mg"},{"description":"Participants with FGF/FGFR gene abnormalities received orally TAS-120 56 mg orally QOD (Monday, Wednesday and Friday of each week) in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.","id":"BG004","title":"Phase 1: Dose Escalation: QOD Dosing: 56 mg"},{"description":"Participants with FGF/FGFR gene abnormalities received orally TAS-120 80 mg orally QOD (Monday, Wednesday and Friday of each week) in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.","id":"BG005","title":"Phase 1: Dose Escalation: QOD Dosing: 80 mg"},{"description":"Participants with FGF/FGFR gene abnormalities received orally TAS-120 120 mg orally QOD (Monday, Wednesday and Friday of each week) in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.","id":"BG006","title":"Phase 1: Dose Escalation: QOD Dosing: 120 mg"},{"description":"Participants with FGF/FGFR gene abnormalities received orally TAS-120 160 mg orally QOD (Monday, Wednesday and Friday of each week) in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.","id":"BG007","title":"Phase 1: Dose Escalation: QOD Dosing: 160 mg"},{"description":"Participants with FGF/FGFR gene abnormalities received orally TAS-120 200 mg orally QOD (Monday, Wednesday and Friday of each week) in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.","id":"BG008","title":"Phase 1: Dose Escalation: QOD Dosing: 200 mg"},{"description":"Participants with or without FGF/FGFR gene abnormalities received a dose between 4 mg orally once daily (QD) in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.","id":"BG009","title":"Phase 1: Dose Escalation: QD Dosing: 4 mg"},{"description":"Participants with or without FGF/FGFR gene abnormalities received a dose between 8 mg orally QD in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.","id":"BG010","title":"Phase 1: Dose Escalation: QD Dosing: 8 mg"},{"description":"Participants with or without FGF/FGFR gene abnormalities received a dose between 16 mg orally QD in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.","id":"BG011","title":"Phase 1: Dose Escalation: QD Dosing: 16 mg"},{"description":"Participants with or without FGF/FGFR gene abnormalities received a dose between 20 mg orally QD in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.","id":"BG012","title":"Phase 1: Dose Escalation: QD Dosing: 20 mg"},{"description":"Participants with or without FGF/FGFR gene abnormalities received a dose between 24 mg orally QD in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.","id":"BG013","title":"Phase 1: Dose Escalation: QD Dosing: 24 mg"},{"description":"Participants with intra-hepatic or extrahepatic cholangiocarcinoma (iCCA or eCCA) harboring FGFR2 gene fusions or rearrangements and who were treated or not treated with prior FGFR inhibitors received TAS-120 20 mg tablets orally QD in each of 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.","id":"BG014","title":"Phase 1: Dose Expansion Cohort 1"},{"description":"Participants with primary central nervous system (CNS) tumors harboring FGFR gene fusions or FGFR1 activating mutations received TAS-120 20 mg tablets orally QD in each of 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.","id":"BG015","title":"Phase 1: Dose Expansion: Cohort 2"},{"description":"Participants with advanced urothelial carcinoma harboring FGFR3 gene fusions or FGFR3 activating mutations received TAS-120 20 mg tablets orally QD in each of 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.","id":"BG016","title":"Phase 1: Dose Expansion: Cohort 3"},{"description":"Participants with breast or gastric cancer with harboring FGFR2 amplification received TAS-120 20 mg tablets orally QD in each of 21- day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.","id":"BG017","title":"Phase 1: Dose Expansion: Cohort 4"},{"description":"Participants with tumor types harboring FGFR gene fusions or activating mutations received TAS-120 20 mg tablets orally QD in each of 21- day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.","id":"BG018","title":"Phase 1: Dose Expansion: Cohort 5"},{"description":"Participants who were not included in Cohorts 1 to 5 received TAS-120 20 mg tablets orally QD in each of 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.","id":"BG019","title":"Phase 1: Dose Expansion: Cohort 6"},{"description":"Participants with iCCA who were enrolled prior to the confirmation of the RP2D received TAS-120 16 mg tablets orally QD in each of 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.","id":"BG020","title":"Phase 1: Dose Expansion: Sub-cohort 1"},{"description":"Participants with other tumor types who were enrolled prior to the confirmation of the RP2D received TAS-120 16 mg tablets orally QD in each of 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.","id":"BG021","title":"Phase 1: Dose Expansion: Sub-cohort 2"},{"description":"Participants with iCCA with tumors harboring FGFR2 gene rearrangements received TAS-120 20 mg tablets orally QD in each of 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.","id":"BG022","title":"Phase 2"},{"description":"Total of all reporting groups","id":"BG023","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"0"},{"groupId":"BG015","value":"0"},{"groupId":"BG016","value":"0"},{"groupId":"BG017","value":"0"},{"groupId":"BG018","value":"0"},{"groupId":"BG019","value":"0"},{"groupId":"BG020","value":"0"},{"groupId":"BG021","value":"0"},{"groupId":"BG022","value":"0"},{"groupId":"BG023","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"3"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"6"},{"groupId":"BG008","value":"5"},{"groupId":"BG009","value":"3"},{"groupId":"BG010","value":"3"},{"groupId":"BG011","value":"12"},{"groupId":"BG012","value":"4"},{"groupId":"BG013","value":"11"},{"groupId":"BG014","value":"45"},{"groupId":"BG015","value":"27"},{"groupId":"BG016","value":"5"},{"groupId":"BG017","value":"10"},{"groupId":"BG018","value":"21"},{"groupId":"BG019","value":"18"},{"groupId":"BG020","value":"18"},{"groupId":"BG021","value":"6"},{"groupId":"BG022","value":"80"},{"groupId":"BG023","value":"290"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"2"},{"groupId":"BG006","value":"3"},{"groupId":"BG007","value":"2"},{"groupId":"BG008","value":"2"},{"groupId":"BG009","value":"1"},{"groupId":"BG010","value":"2"},{"groupId":"BG011","value":"2"},{"groupId":"BG012","value":"3"},{"groupId":"BG013","value":"3"},{"groupId":"BG014","value":"12"},{"groupId":"BG015","value":"7"},{"groupId":"BG016","value":"10"},{"groupId":"BG017","value":"3"},{"groupId":"BG018","value":"3"},{"groupId":"BG019","value":"9"},{"groupId":"BG020","value":"1"},{"groupId":"BG021","value":"2"},{"groupId":"BG022","value":"23"},{"groupId":"BG023","value":"96"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"4"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"4"},{"groupId":"BG008","value":"5"},{"groupId":"BG009","value":"2"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"8"},{"groupId":"BG012","value":"6"},{"groupId":"BG013","value":"13"},{"groupId":"BG014","value":"40"},{"groupId":"BG015","value":"12"},{"groupId":"BG016","value":"4"},{"groupId":"BG017","value":"9"},{"groupId":"BG018","value":"14"},{"groupId":"BG019","value":"16"},{"groupId":"BG020","value":"14"},{"groupId":"BG021","value":"7"},{"groupId":"BG022","value":"58"},{"groupId":"BG023","value":"226"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"3"},{"groupId":"BG007","value":"4"},{"groupId":"BG008","value":"2"},{"groupId":"BG009","value":"2"},{"groupId":"BG010","value":"5"},{"groupId":"BG011","value":"6"},{"groupId":"BG012","value":"1"},{"groupId":"BG013","value":"1"},{"groupId":"BG014","value":"17"},{"groupId":"BG015","value":"22"},{"groupId":"BG016","value":"11"},{"groupId":"BG017","value":"4"},{"groupId":"BG018","value":"10"},{"groupId":"BG019","value":"11"},{"groupId":"BG020","value":"5"},{"groupId":"BG021","value":"1"},{"groupId":"BG022","value":"45"},{"groupId":"BG023","value":"160"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"1"},{"groupId":"BG014","value":"2"},{"groupId":"BG015","value":"0"},{"groupId":"BG016","value":"0"},{"groupId":"BG017","value":"0"},{"groupId":"BG018","value":"0"},{"groupId":"BG019","value":"1"},{"groupId":"BG020","value":"1"},{"groupId":"BG021","value":"2"},{"groupId":"BG022","value":"2"},{"groupId":"BG023","value":"9"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"2"},{"groupId":"BG006","value":"3"},{"groupId":"BG007","value":"3"},{"groupId":"BG008","value":"3"},{"groupId":"BG009","value":"2"},{"groupId":"BG010","value":"3"},{"groupId":"BG011","value":"7"},{"groupId":"BG012","value":"6"},{"groupId":"BG013","value":"6"},{"groupId":"BG014","value":"41"},{"groupId":"BG015","value":"19"},{"groupId":"BG016","value":"7"},{"groupId":"BG017","value":"13"},{"groupId":"BG018","value":"16"},{"groupId":"BG019","value":"23"},{"groupId":"BG020","value":"18"},{"groupId":"BG021","value":"5"},{"groupId":"BG022","value":"89"},{"groupId":"BG023","value":"281"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"3"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"5"},{"groupId":"BG008","value":"4"},{"groupId":"BG009","value":"2"},{"groupId":"BG010","value":"2"},{"groupId":"BG011","value":"7"},{"groupId":"BG012","value":"1"},{"groupId":"BG013","value":"7"},{"groupId":"BG014","value":"14"},{"groupId":"BG015","value":"15"},{"groupId":"BG016","value":"8"},{"groupId":"BG017","value":"0"},{"groupId":"BG018","value":"8"},{"groupId":"BG019","value":"3"},{"groupId":"BG020","value":"0"},{"groupId":"BG021","value":"1"},{"groupId":"BG022","value":"12"},{"groupId":"BG023","value":"96"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"1"},{"groupId":"BG013","value":"2"},{"groupId":"BG014","value":"6"},{"groupId":"BG015","value":"2"},{"groupId":"BG016","value":"0"},{"groupId":"BG017","value":"8"},{"groupId":"BG018","value":"3"},{"groupId":"BG019","value":"2"},{"groupId":"BG020","value":"1"},{"groupId":"BG021","value":"0"},{"groupId":"BG022","value":"30"},{"groupId":"BG023","value":"55"}]}],"title":"Asian/Oriental"},{"categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"3"},{"groupId":"BG007","value":"5"},{"groupId":"BG008","value":"5"},{"groupId":"BG009","value":"3"},{"groupId":"BG010","value":"4"},{"groupId":"BG011","value":"7"},{"groupId":"BG012","value":"6"},{"groupId":"BG013","value":"8"},{"groupId":"BG014","value":"37"},{"groupId":"BG015","value":"17"},{"groupId":"BG016","value":"7"},{"groupId":"BG017","value":"2"},{"groupId":"BG018","value":"15"},{"groupId":"BG019","value":"22"},{"groupId":"BG020","value":"16"},{"groupId":"BG021","value":"7"},{"groupId":"BG022","value":"51"},{"groupId":"BG023","value":"233"}]}],"title":"White/Caucasian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"1"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"1"},{"groupId":"BG015","value":"0"},{"groupId":"BG016","value":"0"},{"groupId":"BG017","value":"2"},{"groupId":"BG018","value":"0"},{"groupId":"BG019","value":"1"},{"groupId":"BG020","value":"1"},{"groupId":"BG021","value":"0"},{"groupId":"BG022","value":"8"},{"groupId":"BG023","value":"15"}]}],"title":"Black or African-American"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"0"},{"groupId":"BG015","value":"0"},{"groupId":"BG016","value":"0"},{"groupId":"BG017","value":"1"},{"groupId":"BG018","value":"0"},{"groupId":"BG019","value":"0"},{"groupId":"BG020","value":"0"},{"groupId":"BG021","value":"0"},{"groupId":"BG022","value":"1"},{"groupId":"BG023","value":"2"}]}],"title":"Native Hawaiian or Other Pacific Islander"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"3"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"3"},{"groupId":"BG008","value":"2"},{"groupId":"BG009","value":"1"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"7"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"4"},{"groupId":"BG014","value":"13"},{"groupId":"BG015","value":"15"},{"groupId":"BG016","value":"8"},{"groupId":"BG017","value":"0"},{"groupId":"BG018","value":"6"},{"groupId":"BG019","value":"2"},{"groupId":"BG020","value":"1"},{"groupId":"BG021","value":"1"},{"groupId":"BG022","value":"13"},{"groupId":"BG023","value":"81"}]}],"title":"Missing/Unknown"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"}],"populationDescription":"Analysis was performed on all treated population."}